Ken Gall
About Ken Gall
Ken Gall serves as Co-Founder and CCO at Reselute and holds multiple board positions across various biomedical companies. He is also a professor at Duke University, specializing in mechanical engineering and the commercialization of synthetic biomaterials.
Work at Restor3d
Ken Gall serves as the Chief Commercial Officer (CCO), Co-Founder, and a member of the Board of Directors at Restor3d. He has held this position since 2017, contributing to the company's mission in Durham, North Carolina. His role involves overseeing commercial strategies and initiatives, reflecting his extensive background in engineering and entrepreneurship.
Education and Expertise
Ken Gall obtained a Bachelor of Science (BS) in Mechanical Engineering from the University of Illinois Urbana-Champaign from 1992 to 1995. He continued his education at the same institution, earning a Master of Science (MS) in Mechanical Engineering from 1995 to 1996, followed by a PhD in the same field from 1996 to 1998. His academic background supports his expertise in engineering and materials science.
Background
Ken Gall combines roles in academia and entrepreneurship, reflecting a unique blend of theoretical knowledge and practical application in engineering. He has been a professor at Duke University since 2015 and currently holds the position of Associate Dean of Entrepreneurship. His work emphasizes the commercialization of synthetic biomaterials, particularly in the orthopaedic space.
Achievements
Ken Gall has contributed to the field of biomaterials through various initiatives. He has been involved in the development of 3D printed porous titanium implants for critical-sized bone defects and has researched the mechanical behavior of 3D printed titanium scaffolds. Additionally, he has co-authored several scientific papers on 3D printing and biomaterials, showcasing his commitment to advancing the field.
Board Memberships and Collaborations
In addition to his role at Restor3d, Ken Gall serves on the Board of Directors for multiple organizations, including Synergy Biomedical, Orthobond Corporation, Sparta Biomedical, and PROTECT3D. He co-founded Huxley Medical, Inc. in 2019. His involvement in these companies highlights his dedication to innovation in the biomedical field.